XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.3
Sale of PerClot (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
May 23, 2023
Jul. 28, 2021
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Proceeds from sale of assets         $ 0 $ 14,250
Gain (loss) on disposition     $ 0 $ 0 0 14,250
Revenue     95,779 87,854 291,229 260,334
Per Clot            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Consideration for sale of assets   $ 41,000        
Gain (loss) on disposition           14,300
Revenue     $ 994 $ 2,000 $ 2,300 $ 3,600
Per Clot | Transfer Of Perclot Manufacturing Equipment            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Contingent consideration receivable   780        
Per Clot | SMI            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Contingent liability payment $ 4,500 4,500        
Per Clot | Upon Our Receipt of Premarket Approval            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Proceeds from sale of assets   18,800        
Per Clot | Artivion Inc. And Starch Medical Inc.            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Consideration for sale of assets   54,500        
Proceeds from sale of assets $ 18,800 25,000        
Per Clot | Artivion Inc. And Starch Medical Inc. | Baxter Achievement Of Worldwide Sales            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Contingent consideration receivable   $ 10,000        
Contractual period   21 months        
Per Clot | SMI            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Consideration for sale of assets   $ 13,500        
Proceeds from sale of assets   6,000        
Per Clot | SMI | Baxter Achievement Of Worldwide Sales            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Contingent consideration receivable   $ 3,000